Xenon Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2016 Annual Meeting of Shareholders held by Xenon Pharmaceuticals Inc. on June 2, 2016. The filing was submitted on June 3, 2016.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Shareholders representing approximately 62.4% of total shares entitled to vote (8,994,808 shares) participated in the meeting. Three proposals were approved:
- Proposal One (Election of Directors): All eight nominees were elected to serve until the 2017 annual meeting. Michael Hayden and Simon Pimstone received the highest "For" votes (7,662,770 and 7,663,846 respectively), while Frank Holler received the lowest "For" votes (5,765,317) among the nominees.
- Proposal Two (Appointment of Auditor): KPMG LLP was appointed as the independent registered public accounting firm for the ensuing year with 8,914,258 votes "For" and 80,550 "Withhold".
- Proposal Three (Auditor Remuneration): The Audit Committee was authorized to set auditor remuneration with 8,910,811 votes "For" and 83,995 "Against".
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the full composition of the newly elected Board of Directors and their tenure terms.
- Confirm the engagement letter and fee structure with KPMG LLP for the upcoming fiscal year.
- Review the definitive proxy statement filed on April 27, 2016, for detailed biographies of directors and rationale for auditor selection.
- Note that 1,251,305 broker non-votes were recorded for the director elections, indicating shares held in street name where brokers lacked discretionary voting power.